Stimulation of site-specific topoisomerase II-mediated DNA cleavage by an N-methylpyrrolecarboxamide-anilinoacridine conjugate: relation to DNA binding.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Biochemistry

• Publication date

  1994-08-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI00199A007PMID 8060993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.

  1994cited by this paper
• Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers.

  1993cited by this paper
• Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.

  1993cited by this paper
• Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.

  1993cited by this paper
• Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.

  1993cited by this paper
• Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.

  1993cited by this paper
• Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.

  1993cited by this paper
• Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship.

  1992cited by this paper
• Drug—DNA sequence‐dependent interactions analysed by electric linear dichroism

  1992cited by this paper
• Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.

  1992cited by this paper
• Biological activity and molecular interaction of a netropsin-acridine hybrid ligand with chromatin and topoisomerase II.

  1992cited by this paper
• Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.

  1991cited by this paper
• Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.

  1991cited by this paper
• DNA intercalating anti-tumour agents.

  1991cited by this paper
• Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

  1991cited by this paper
• DNA recognition by intercalator-minor-groove binder hybrid molecules.

  1991cited by this paper
• Design of NDA Intercalators To Overcome Topoisomerase II-Mediated Multidurg Resistance

  1990cited by this paper
• Molecular recognition between oligopeptides and nucleic acids. DNA sequence specificity and binding properties of an acridine‐linked netropsin hybrid ligand

  1990cited by this paper
• Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.

  1990cited by this paper
• Stimulation by gamma-carboline derivatives (simplified analogues of antitumor ellipticines) of site specific DNA cleavage by calf DNA topoisomerase II.

  1990cited by this paper
• Stimulation by γ-carboline derivatives (simplified analogues of antitumor ellipticines) of site specific DNA cleavage by calf DNA topoisomerase II

  1990cited by this paper
• In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.

  1989cited by this paper
• DNA-intercalating ligands as anti-cancer drugs: prospects for future design.

  1989cited by this paper
• Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA.

  1989cited by this paper
• DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989cited by this paper
• Design, synthesis, DNA binding, and biological activity of a series of DNA minor-groove-binding intercalating drugs.

  1989cited by this paper
• Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole.

  1989cited by this paper
• A new revision of the sequence of plasmid pBR322.

  1988cited by this paper
• Inhibition of type II topoisomerase by fostriecin.

  1988cited by this paper
• Single-strand DNA cleavages by eukaryotic topoisomerase II.

  1988cited by this paper
• DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition.

  1988cited by this paper
• Inhibitors of DNA topoisomerases.

  1988cited by this paper
• Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines.

  1987cited by this paper
• Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.

  1987cited by this paper
• Nucleic acid binding drugs--XIV. The crystal structure of 1-methyl amsacrine hydrochloride; relationships to DNA-binding ability and anti-tumour activity.

  1986cited by this paper
• Design of sequence-specific DNA-binding molecules.

  1986cited by this paper
• Formation of the thiol adducts of 4'-(9-acridinylamino)methanesulfon-m-anisidide and their binding to deoxyribonucleic acid.

  1986cited by this paper
• DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.

  1986cited by this paper
• Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.

  1986cited by this paper
• Amsacrine: a review.

  1986cited by this paper
• DNA topoisomerases.

  1985cited by this paper
• Purification and characterization of a type II DNA topoisomerase from bovine calf thymus.

  1985cited by this paper
• Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.

  1984cited by this paper
• Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.

  1984cited by this paper
• Mechanism of deoxyribonucleic acid breakage induced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and copper: role for cuprous ion and oxygen free radicals.

  1984cited by this paper
• Interaction of 4-(9-acridinylamino)aniline and derivatives with DNA. Influence of a lysylglycyl side chain on the binding parameters.

  1982cited by this paper
• Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

  1981cited by this paper
• Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids.

  1981cited by this paper
• A homogeneous type II DNA topoisomerase from HeLa cell nuclei.

  1981cited by this paper
• Sequencing end-labeled DNA with base-specific chemical cleavages.

  1980cited by this paper
• Induction of limited DNA damage by the antitumor agent Cain's acridine.

  1978cited by this paper
• DNA-binding characteristics of acridinylmethanesulphonanilide drugs: comparison with antitumour properties.

  1976cited by this paper
• Potential antitumor agents. 16.4'-(Acridin-9-ylamino)methanesulfonanilides.

  1975cited by this paper
• The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.

  1974cited by this paper
• Physicochemical studies on polydeoxyribonucleotides containing defined repeating nucleotide sequences.

  1970cited by this paper

• Synthesis and anticancer evaluation of sulfur containing 9-anilinoacridines.

  2021cites this paper
• Synthesis, Characterization and Antitumour Activity of Some Novel Oxazine Substituted 9-Anilinoacridines and their 3D-QSAR Studies

  2018cites this paper
• Integrated scientific data bases review on asulacrine and associated toxicity.

  2016cites this paper
• Synthesis of batracylin and its N-sulfonamido analogues in [b-3C-im][NTf2] ionic liquid

  2014cites this paper
• Role of Minor Groove Width and Hydration Pattern on Amsacrine Interaction with DNA

  2013cites this paper
• Correction: Role of Minor Groove Width and Hydration Pattern on Amsacrine Interaction with DNA

  2013cites this paper
• Synthesis and antitumor activity of sulfur-containing 9-anilinoacridines.

  2005cites this paper
• Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin.

  2004cites this paper
• Antitumour acridines

  2004cites this paper
• Design of a Composite Ethidium–Netropsin–Anilinoacridine Molecule for DNA Recognition

  2003cites this paper
• CONCEPTION, SYNTHESE ET EVALUATION PHARMACOLOGIQUE DE PYRROLO(3,4-b)QUINOLEINES CONDENSEES, LIGANDS POTENTIELS DE L'ADN

  2003cites this paper
• Selection of an unnatural peptide library for dsDNA binding.

  2001cites this paper
• Interest of acridine derivatives in the anticancer chemotherapy.

  2001cites this paper
• Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.

  2000cites this paper
• Synthesis and cytotoxicity of analogues of the antibiotic BE 10988 inhibitors of DNA topoisomerase II.

  1999cites this paper
• Sequence-specific poisons of type II DNA topoisomerases

  1998cites this paper
• Sequence-specific recognition and modification of double-helical DNA by minor-groove binding conjugates structurally related to netropsin and distamycin

  1998cites this paper
• Sequence-specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues.

  1998cites this paper
• A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.

  1997cites this paper
• [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].

  1997cites this paper
• Interaction of DNA-threading peptide-amsacrine conjugates with DNA and chromatin.

  1996cites this paper
• The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.

  1996cites this paper
• Interaction of a DNA-threading netropsin-amsacrine combilexin with DNA and chromatin.

  1996cites this paper
• Design of composite drug molecules: mutual effects on binding to DNA of an intercalator, amsacrine, and a minor groove binder, netropsin.

  1995cites this paper
• Chromosomes and expression mechanisms

  1995cites this paper
• Topoisomerase II as a target for anticancer chemotherapy.

  1995cites this paper